Microarrays

Korea NIH to Use Affymetrix Technology for Groundbreaking Genome-Wide Association Study

Published in Medical Letter on the CDC and FDA, July 1st, 2007

Affymetrix Inc. (Nasdaq:AFFX) announced that the Republic of Korea's National Institute of Health (NIH) and Center for Disease Control and Prevention will use the Affymetrix Genome-Wide Human SNP Array 5.0 for the Korean Association REsource (KARE) project. This groundbreaking genome-wide association study is designed to identify the genetic causes of lifestyle-related complex diseases that are prevalent in Korea.

The KARE project is expected to be one of the world's most recognizable clinical research projects. Researchers will use the Affymetrix microarray technology to generate individual genotypes from more than 10,000 human DNA samples. The technology enables...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2007-07-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry